Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Shannon N. Westin, Michael W. Sill, Robert L. Coleman, Steven Waggoner, Kathleen N. Moore, Cara A. Mathews, Lainie P. Martin, Susan C. Modesitt, Sanghoon Lee, Zhenlin Ju, Gordon B. Mills, Russell J. Schilder, Paula M. Fracasso, Michael J. Birrer, Carol Aghajanian

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study'. Together they form a unique fingerprint.

Medicine & Life Sciences